The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1611
ISSUE 1611
November 16, 2020
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
November 16, 2020 (Issue: 1611)
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
Article code: 1611e
Electronic, downloadable article - $45
Article code: 1611e
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
